CSPC says China regulator accepts NDA for Anbenitamab, albumin-bound docetaxel breast cancer combo under priority review

PUBT · 2d ago
CSPC says China regulator accepts NDA for Anbenitamab, albumin-bound docetaxel breast cancer combo under priority review
  • CSPC said China’s NMPA accepted its NDA for anbenitamab (KN026) with albumin-bound docetaxel (HB1801) in first-line advanced HER2-positive breast cancer.
  • The filing entered the priority review channel.
  • KN026 is co-developed with Jiangsu Alphamab Oncology; the regimen previously received NMPA breakthrough therapy designation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260818-12288841), on August 18, 2026, and is solely responsible for the information contained therein.